Home > Healthcare > Biotechnology > Bioservices > Cell & Gene Therapy Manufacturing Services Market

Cell & Gene Therapy Manufacturing Services Market Size

Report ID: GMI5689
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Cell & Gene Therapy Manufacturing Services Market Size

Cell & Gene Therapy Manufacturing Services Market size was valued at USD 5.9 billion in 2023 and is projected to grow at a CAGR of 18.9% between 2024 and 2032. The substantial growth in the market can be attributed to biotechnological advancements facilitating the development of cutting-edge cell and gene therapies, which hold promise in treating various diseases such as genetic disorders and cancers.

To get key market trends

Download Free Sample

With rising number of therapies transitioning from preclinical stages to clinical trials and commercialization, the need for specialized manufacturing services is surging to facilitate their production bolstering market demand. Moreover, regulatory agencies are streamlining approval processes, enhancing investor trust, and stimulating investments in manufacturing infrastructure and technology has further explored opportunities in the market.

The market refers to the types provided by contract manufacturing organization (CMOs) and contract development and manufacturing organizations (CDMOs) to support the development of manufacturing commercialization of gene and cell therapies. These types include process development, cell line development, analytical testing, clinical and commercial manufacturing, and regulatory support.

Cell & Gene Therapy Manufacturing Services Market Report Attributes
Report Attribute	Details
Base Year:	2023
Cell & Gene Therapy Manufacturing Services Market Size in 2023:	USD 5.9 Billion
Forecast Period:	2024 to 2032
Forecast Period 2024 to 2032 CAGR:	18.9%
2032 Value Projection:	USD 28.7 Billion
Historical Data for:	2021 - 2023
No. of Pages:	114
Tables, Charts & Figures:	422
Segments covered:	Type, Mode, Indication, End-user, & Region
Growth Drivers:	Increasing prevalence of cancer and other diseases Increasing government grants and support for development of cell and gene therapies Increasing pharmaceutical R&D spending
Pitfalls & Challenges:	High risk of mutagenesis Lack of standardized production systems for cell and gene therapy products

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cell & gene therapy manufacturing services industry was valued at USD 5.9 billion in 2023 and is projected to record a CAGR of 18.9% between 2024 – 2032, attributed to biotechnological advancements, which hold promise in treating various diseases such as genetic disorders and cancers.

In 2023, the biopharmaceutical companies segment held 69.4% share in the cell and gene therapy manufacturing services market, attributed to their significant investments in R&D, as well as their extensive expertise in drug discovery and development.

North America cell & gene therapy manufacturing services market is anticipated to record a CAGR of 18.1% through 2032, attributed to the regions growing participation in related R&D, rising cancer cases, as well as a large number of contract development manufacturing organizations.

Catalent, Inc., Charles River Laboratories International, Inc., Merck KGaA, Miltenyi Bioindustry (Miltenyi Biotec), Samsung Biologics, and Takara Bio Inc.